Impact Analysis of Covid-19 The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters. Request Sample

Auto-Injectors Market – Insights

Auto-injectors are used to deliver a dose of a particular drug. Epinephrine auto-injector is a type of auto-injector widely used for people at risk of anaphylaxis. Auto-injectors are often used in the military to protect personnel from chemical warfare agents.

The global auto-injectors market is estimated to account for US$ 2,338.2 Mn in 2018 in terms of value and is expected to reach US$ 7,894.6 Mn by the end of 2027.

Global Auto-Injectors Market: Drivers

Increasing prevalence of multiple sclerosis (MS) is expected to boost growth of the global auto-injectors market over the forecast period. For instance, according to a study by National MS Society, published in February 2019, in the journal Neurology, in 2017, nearly 1 million adults were living with MS in the U.S.

Moreover, increasing number of people suffering from anaphylaxis is also expected to aid in growth of the market. For instance, according to the study, ‘The Global Incidence and Prevalence of Anaphylaxis in Children in The General Population: A Systematic Review, published in January 2019, in the European Journal of Allergy and Clinical Immunology, the incidence of anaphylaxis in children worldwide ranged from 1 to 761 per 100 000 person?years for total anaphylaxis and 1 to 77 per 100 000 person?years for food?induced anaphylaxis.

North America region held dominant position in the global auto-injectors market in 2018, accounting for 75.9% share in terms of value, followed by Europe.

Global Auto-Injectors Market: Restraints

High cost of auto-injectors is a major factor hindering growth of the global auto-injectors market. For instance, the cost of EpiPen (2-pack) increased from US$ 100 in 2007 to US$ 608. Moreover, the cost of a generic EpiPen launched in December 2016 was 300% more than that in 2007.

Moreover, stringent regulatory scenario for approval of auto-injectors is also expected to hinder growth of the market. The U.S. FDA classifies auto-injectors as class II high-risk medical devices and are subject to additional control prior to receiving approval.

Global Auto-Injectors Market: Opportunities

The market in Europe is witnessing increasing shortages of epinephrine auto-injectors following manufacturing issues with the Emerade brand auto-injector. Therefore, key players in the market can focus on expanding their presence in the region.

Blockage in the needle in adrenaline auto-injectors is a common issue and may lead to failure in delivery of a dose. This increases the need for proper training and advice for patients and caregivers before using the devices. Key players can encourage end users to sign up for the Expiry Alert Service of their auto-injectors.

Prefilled Auto-Injectors sub segment in the product type segment in global auto-injectors market was valued at US$ 1,904.1 Mn in 2018 and is expected to reach US$ 7,266.6 Mn by 2027 at a CAGR of 15.1% during the forecast period.

Market Trends/Key Takeaways

The market is witnessing increasing launch of auto-injectors for infants and toddlers. For instance, in July 2019, Walgreens, a pharmacy store chain, and Kaléo, a privately-held pharmaceutical company, announced AUVI-q (epinephrine injection, USP) 0.1 mg auto-injector – the first and only epinephrine auto-injector approved by the U.S. FDA for infants and toddlers is available at Walgreens locations.

Key players in the market are also focused on launching disposable auto-injectors. For instance, in October 2019, Becton, Dickinson and Company launched the BD Intevia 1mL two-step disposable auto-injector.

Regulations:

U.S.

Pen injectors for general use are regulated as class II devices under 21 CFR 880.5860 (product code NSC) or 21 CFR 880.6920

Jet injectors for general use, including needle or needle-free injectors, are regulated as class II devices under 21 CFR 880.5430

999 Epinephrine Auto-Injector Minnesota allows authorized entities including recreation camps, colleges, universities, preschools and day-care facilities to obtain, store, and use epinephrine auto-injectors without a prescription

Global Auto-Injectors Market: Competitive Landscape

Major players operating in the global auto-injectors market include, Becton, Dickinson and Company, Sanofi, Pfizer, Inc., Mylan N.V., Novartis International AG, Bayer AG, Janssen Global Services, LLC, Antares Pharma, Inc., Amgen Inc., and Eli Lilly and Company.

Global Auto-Injectors Market: Key Development

Major players in the market are focused approval and launch of generic products to enhance their market share. For instance, in August 2019, Teva Pharmaceutical Industries Ltd. launched generic version of Mylan’s EpiPen for young children.

Key players in the market are also focused on adopting partnership strategies to expand their product portfolio. For instance, in October 2019, Haselmeier, a manufacturer of self-injection devices, partnered with Stevanato Group, a producer of glass primary packaging based in Italy, for development, manufacturing, and supply of the axis-D pen-injector in the therapeutic area of diabetes care.